"The combination of scientific and institutional integrity represented by this book is unusual. It should be a model for future endeavors to help quantify environmental risk as a basis for good decisionmaking." â€"William D. Ruckelshaus, from the foreword. This volume, prepared under the auspices of the Health Effects Institute, an independent research organization created and funded jointly by the Environmental Protection Agency and the automobile industry, brings together experts on atmospheric exposure and on the biological effects of toxic substances to examine what is knownâ€"and not knownâ€"about the human health risks of automotive emissions.
Inhaled medicines are widely used to treat pulmonary and systemic diseases. The efficacy and safety of these medicines can be influenced by the deposited fraction, the regional deposition pattern within the lungs and by post-depositional events such as drug dissolution, absorption and clearance from the lungs. Optimizing performance of treatments thus requires that we understand and are able to quantify these product and drug attributes. Inhaled Medicines: Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches explores the current state of the art with respect to inhalation drug delivery, technologies available to assess product performance, and novel in silico methods now available to link in vitro product performance to clinical performance. Recent developments in the latter field, especially the prospect of integration of three-dimensional Computational Fluid Particle Methods (3D-CFPD) with physiologically based pharmacokinetic (PBPK models), unlocks the potential for in silico population studies that can help inform and optimize treatment and product development strategies. In this highly multidisciplinary field, where progress occurs at the intersection of several disciplines of engineering and science, this work aims to integrate current knowledge and understanding and to articulate a clear vision for future developments. ? Considers the healthcare needs driving the field, and where inhaled drugs could have the maximum impact ? Gives a concise account of the state of the art in key areas and technologies such as device and formulation technologies, clinically relevant in vitro performance assessment, medical imaging, as well as in silico modelling and simulation ? Articulates how the combination of in vitro product performance data, medical imaging and simulations technologies in the framework of large scale in silico pre-clinical trials could revolutionize the field ? Provides systematic and thorough referencing to sources offering a more-in-depth analysis of technical issues
Drug therapy via inhalation route is at the cutting edge of modern drug delivery research. There has been significant progress on the understanding of drug therapy via inhalation products. However, there are still problems associated with their formulation design, including the interaction between the active pharmaceutical ingredient(s) (APIs), excipients and devices. This book seeks to cover some of the most pertinent issues and challenges of such formulation design associated with industrial production and desirable clinical outcome. The chapter topics have been selected with a view to integrating the factors that require consideration in the selection and design of device and formulation components which impact upon patient usability and clinical effectiveness. The challenges involved with the delivery of macromolecules by inhalation to both adult and pediatric patients are also covered. Written by leading international experts from both academia and industry, the book will help readers (formulation design scientists, researchers and post-graduate and specialized undergraduate students) develop a deep understanding of key aspects of inhalation formulations as well as detail ongoing challenges and advances associated with their development.
The #1 guide to aerosol science and technology -now better than ever Since 1982, Aerosol Technology has been the text of choice among students and professionals who need to acquire a thorough working knowledge of modern aerosol theory and applications. Now revised to reflect the considerable advances that have been made over the past seventeen years across a broad spectrum of aerosol-related application areas - from occupational hygiene and biomedical technology to microelectronics and pollution control -this new edition includes: * A chapter on bioaerosols * New sections on resuspension, transport losses, respiratory deposition models, and fractal characterization of particles * Expanded coverage of atmospheric aerosols, including background aerosols and urban aerosols * A section on the impact of aerosols on global warming and ozone depletion. Aerosol Technology, Second Edition also features dozens of new, fully worked examples drawn from a wide range of industrial and research settings, plus new chapter-end practice problems to help readers master the material quickly.
The respiratory tract has been used to deliver biologically active chemicals into the human body for centuries. However, the lungs are complex in their anatomy and physiology, which poses challenges to drug delivery. Inhaled formulations are generally more sophisticated than those for oral and parenteral administration. Pulmonary drug development is therefore a highly specialized area because of its many unique issues and challenges. Rapid progress is being made and offers novel solutions to existing treatment problems. Advances in Pulmonary Drug Delivery highlights the latest developments in this field.
Pulmonary Deposition and Retention of Inhaled Aerosols is concerned with the respiratory deposition and retention of inhaled aerosols, starting with initial intake and concluding with events that precede pathological tissue response, drawing equally upon both the physical and biological aspects of the subject. The book opens with an introductory chapter on the relationship between the dose of an inhaled aerosol and the kind and degree of response, and classification of particulate substances. This is followed by separate chapters on pulmonary deposition and retention of inhaled aerosols; the factors that influence disease risks associated with atmospheric exposure to aerosols; and measurement of aerosol composition and concentration. It is hoped that the book will help the specialists from both sides as well as technical and administrative personnel to acquire a common understanding of the important intermediate factors that operate between the outside dusty atmosphere and the internal tissue damage and disease—factors that may operate to make one exposure dangerous to life and another altogether innocuous.
Studies of underground miners have provided a wealth of data about the risk of lung cancer from exposure to radon's progeny elements, but the application of the miner data to the home environment is not straightforward. In Comparative Dosimetry of Radon in Mines and Homes, an expert committee uses a new dosimetric model to extrapolate to the home environment the risk relationships found in the miner studies. Important new scaling factors are developed for applying risk estimates based on miner data to men, women, and children in domestic environments. The book includes discussions of radon dosimetry and the uncertainties concerning other risk factors such as age and smoking habits. The book also contains a thorough technical discussion of the characteristics of radioactive aerosols in domestic environments, the dose of inhaled radon progeny to different age groups, identification of respiratory tract cells at the greatest risk of carcinogenesis, and a complete description of the new lung dose model being developed by the International Commission on Radiological Protection as modified by this committee.
This book assesses the most appropriate forms of aerosol therapy for critically ill patients. Aerosol therapy is applied for the treatment of several pulmonary diseases in addition to some promising applications intended for systemic absorption. Nowadays, aerosol delivery to clinically stable patients in the outpatient settings is done easily with a lot of focus on patient counseling and enhancement of lung deposition. A lot of guidelines are available for several diseases and it could offer adequate guidance to the therapists concerning escalation or de-escalation of therapy to enhance treatment efficiency and safety. However, in critically ill patients aerosol delivery is mostly done by the choice of the respiratory therapist only according to his knowledge. The book describes the type of patients requiring aerosol therapy, different aerosol generators available for the treatment of critically ill patients, mechanisms of aerosol lung deposition, and factors affecting aerosol deposition. It also discusses the special needs of neonates and infants, transitioning aerosol from hospital to home, and the methods of aerosol delivery to different patient e.g. nasal delivery patients, ventilated patients, etc. Moreover, it reviews methods of detecting such aerosol delivery to the lung. At the end, it discusses the suggested monitoring plans and weaning protocols to ensure high efficacy and safety of the ventilatory support in such patients. Given its scope, the book can serve as guidelines or specific recommendations to maximize clinical benefits of medicated aerosols in critically ill patients and it represents a valuable resource for intensivists, pulmonologists and healthcare professionals working at ICUs.
Biologic markersâ€"indicators of biological exposure or changeâ€"offer the promise of early detection of disease caused by environmental exposure. Researchers have used these markers to discover indications of pulmonary damage from low-level ozone, a finding with serious implications for health professionals and environmental regulators. Biologic Markers in Pulmonary Toxicology is a comprehensive study of this use of biologic markers. Focusing on the respiratory tract as an entryway for airborne pollutants, this volume reviews new ways of measuring markers, the need for markers to indicate dose or exposure levels, noninvasive respiratory function tests for use with healthy humans to detect sensitivity to inhaled pollutants, approaches to evaluating markers down to the cellular and biochemical levels, and more.
